Other languages VACY AS Oslo Bors

Equities

VACC

NO0010714785

End-of-day quote Oslo Bors Other stock markets			5-day change	1st Jan Change
- ^PTS	-.--%		-.--%	-.--%

14/05	Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024
14/05	Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14/05
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19/04
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21/03
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19/03
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14/12
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	29/23/29
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	29/23/29
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	20/23/20
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	05/23/05
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/23/23
Nykode Adds New Cancer Vaccine Candidate in Clinical Trial Tie-up With Roche	01/23/01
Nykode Therapeutics Announces Expansion of Clinical Collaboration with Roche to Evaluate VB10.16 in Combination with anti-PD-L1 in the Next Trial in Advanced Cervical Cancer	01/23/01
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Nykode Therapeutics AS Announces Management Changes	11/23/11
Nykode Therapeutics AS Announces Positive Final Results from its Phase 2 Trial of VB10.16 in Combination with PD-L1 Inhibitor Atezolizumab in Advanced Cervical Cancer	18/23/18
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	28/23/28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages VACY AS Oslo Bors

Equities

VACC

NO0010714785

Other languages

Filters